StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
LINKPH.BO$27.00+0.00%
Fair $27.00+0.0%

LINKPH.BO

Link Pharma Chem Limited

Basic Materials / ChemicalsBSE

$27.00

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $27.00Fund rank 23/100 · Data gapFallback financials|
SA 19/F
F-Score: 6/9
Declining RevenueLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 17%

FCF escenarios

weak_data · normalized FCF $-280000.00 · quality 39.7/100

Data gap 23/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 6/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

19/100

F

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists. Revenue has declined for 3 consecutive years ROE is -8.1%, below the 5% threshold
Thesis & Journal · LINKPH.BOLocal privado en este navegador · Link Pharma Chem Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$120M

P/E

93.1x

↑

EV/EBITDA

56.1x

↑

ROE

-8.1%

↓

Gross Margin

50.7%

↑

Debt/Equity

0.46

↑
52-Week Range$27
$21$43

TradingView lightweight chart

LINKPH.BO price, volumen y niveles de valoración

Último $27.00Periodo -34.5%
Fair value: $27.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-22.0%

FCF CAGR

—

FCF margin

10.6%

FCF / Net income

-2.61x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $254.3M · net income $-10.3M · FCF $26.9M

2022-FY → 2025-FY

Gross margin

50.7%+22.2% pts

Operating margin

-3.2%-8.0% pts

Net margin

-4.0%-7.6% pts

FCF margin

10.6%+15.1% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$254.3M$254.3M$299.0M$387.6M$535.6M
Net Income$-10.3M$-10.3M$-13.6M$6.5M$18.8M
EBITDA$3.2M$3.2M$-95000.00$25.6M$39.6M
EPS-2.31-2.31-3.071.474.24
Gross Margin50.7%50.7%36.3%40.1%28.5%
Operating Margin-3.2%-3.2%-5.6%5.7%4.8%
Net Margin-4.0%-4.0%-4.6%1.7%3.5%
Balance Sheet
Debt/Equity0.460.460.670.580.44
Current Ratio1.011.01———
Cash Flow
Free Cash Flow$26.9M$26.9M$-280000.00$-26.0M$-24.1M
Returns
ROE-8.1%-8.1%-9.9%4.3%13.0%
Valuation
P/E93.1093.10———
EV/EBITDA56.0556.05———
P/B0.950.95———
Growth & Yield
Revenue Growth-14.9%-14.9%-22.9%-27.6%—
EPS Growth24.8%24.8%-308.8%-65.3%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -24.4%

Total return

-24.4%

Start / end P/E

n/dx → n/dx

EPS bridge

-3.07 → -2.31

Residual

-24.4%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-24.4%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.